Eli Lilly's experimental weight‑loss drug retatrutide shows strong trial results, fuels US demand despite lack of FDA OK

Eli Lilly reported Phase 3 trial data for its experimental GLP‑1 drug retatrutide, showing average weight loss of up to 30% at the highest dose and about 19% at the lower 4 mg dose in people with type 2 diabetes. Separate obesity studies presented at the American Diabetes Association showed up to 28.3% weight loss and significant improvements in A1C, cholesterol, and blood pressure. The results lifted Lilly’s shares about 5% in pre‑market trading, pushing the stock toward record highs and reinforcing bullish sentiment among retail investors.

Despite the promising outcomes, the drug is not yet FDA‑approved. Investigations have found that clinics and online pharmacies across the United States are offering retatrutide to patients willing to pay out‑of‑pocket. Experts warn of safety risks, noting GLP‑1 drugs can cause muscle and bone loss, malnutrition, and gallstones. “That is quite staggering,” said Dr. Harpreet Singh Bajaj, a study author, while obesity specialist Dr. Caroline Apovian warned that rapid weight loss can erode lean mass.

The story highlights a clash between strong clinical data, market enthusiasm, and regulatory uncertainty as consumers chase a drug that could reshape the $150 billion GLP‑1 market forecast for 2030.